JP2022521474A5 - - Google Patents

Info

Publication number
JP2022521474A5
JP2022521474A5 JP2021546232A JP2021546232A JP2022521474A5 JP 2022521474 A5 JP2022521474 A5 JP 2022521474A5 JP 2021546232 A JP2021546232 A JP 2021546232A JP 2021546232 A JP2021546232 A JP 2021546232A JP 2022521474 A5 JP2022521474 A5 JP 2022521474A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
formula
ceremony
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521474A (ja
JP7526734B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/050982 external-priority patent/WO2020161675A1/en
Publication of JP2022521474A publication Critical patent/JP2022521474A/ja
Publication of JP2022521474A5 publication Critical patent/JP2022521474A5/ja
Application granted granted Critical
Publication of JP7526734B2 publication Critical patent/JP7526734B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546232A 2019-02-08 2020-02-07 アルギナーゼインヒビタ及びその使用方法 Active JP7526734B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802765P 2019-02-08 2019-02-08
US62/802,765 2019-02-08
PCT/IB2020/050982 WO2020161675A1 (en) 2019-02-08 2020-02-07 Arginase inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022521474A JP2022521474A (ja) 2022-04-08
JP2022521474A5 true JP2022521474A5 (cg-RX-API-DMAC7.html) 2023-01-31
JP7526734B2 JP7526734B2 (ja) 2024-08-01

Family

ID=69770954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021546232A Active JP7526734B2 (ja) 2019-02-08 2020-02-07 アルギナーゼインヒビタ及びその使用方法

Country Status (32)

Country Link
US (2) US12435097B2 (cg-RX-API-DMAC7.html)
EP (1) EP3921033B1 (cg-RX-API-DMAC7.html)
JP (1) JP7526734B2 (cg-RX-API-DMAC7.html)
KR (1) KR102759971B1 (cg-RX-API-DMAC7.html)
CN (1) CN113395996B (cg-RX-API-DMAC7.html)
AU (1) AU2020218651B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015581A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002056A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021011039A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210463A (cg-RX-API-DMAC7.html)
DK (1) DK3921033T3 (cg-RX-API-DMAC7.html)
DO (2) DOP2021000166A (cg-RX-API-DMAC7.html)
EA (1) EA202192114A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960034T3 (cg-RX-API-DMAC7.html)
FI (1) FI3921033T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231092T1 (cg-RX-API-DMAC7.html)
HU (1) HUE062968T2 (cg-RX-API-DMAC7.html)
IL (1) IL285108B2 (cg-RX-API-DMAC7.html)
LT (1) LT3921033T (cg-RX-API-DMAC7.html)
MA (1) MA56324B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021009499A (cg-RX-API-DMAC7.html)
MY (1) MY206577A (cg-RX-API-DMAC7.html)
PE (1) PE20220280A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551902A1 (cg-RX-API-DMAC7.html)
PL (1) PL3921033T3 (cg-RX-API-DMAC7.html)
PT (1) PT3921033T (cg-RX-API-DMAC7.html)
RS (1) RS64781B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108503PA (cg-RX-API-DMAC7.html)
SI (1) SI3921033T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300337T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020161675A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202105833B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
SE0300907D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Novel compounds
WO2010085797A2 (en) 2009-01-26 2010-07-29 The Trustees Of University Of Pennsylvania Arginase inhibitors and methods of use
EP2560978B1 (en) * 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
EP3034509B1 (en) * 2010-10-26 2020-04-22 Mars, Incorporated Arginase inhibitors as therapeutics
CA2852685C (en) 2011-10-19 2019-02-26 Mars, Incorporated Inhibitors of arginase and their therapeutic application
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
PL410665A1 (pl) * 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2017175185A1 (en) * 2016-04-08 2017-10-12 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
WO2018119440A1 (en) * 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
CN108794517B (zh) * 2017-04-27 2021-03-30 南京谷睿生物科技有限公司 一种精氨酸酶抑制剂及其制备方法与用途
SG11202007739XA (en) * 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) * 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) * 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途
MA53427B1 (fr) 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation

Similar Documents

Publication Publication Date Title
JP2024050527A5 (cg-RX-API-DMAC7.html)
JP2023520333A5 (cg-RX-API-DMAC7.html)
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
JP2021063088A5 (cg-RX-API-DMAC7.html)
JP2024001048A5 (cg-RX-API-DMAC7.html)
JP2022534426A5 (cg-RX-API-DMAC7.html)
JP2021519783A5 (cg-RX-API-DMAC7.html)
JP5576485B2 (ja) 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール
JP2012530703A5 (cg-RX-API-DMAC7.html)
JP2020507589A5 (cg-RX-API-DMAC7.html)
JP2019517487A5 (cg-RX-API-DMAC7.html)
JP2022544714A5 (cg-RX-API-DMAC7.html)
JP2019510787A5 (cg-RX-API-DMAC7.html)
JP2014503574A5 (cg-RX-API-DMAC7.html)
JP2020517707A5 (cg-RX-API-DMAC7.html)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2010540508A5 (cg-RX-API-DMAC7.html)
JP2021535112A5 (cg-RX-API-DMAC7.html)
JP2014532716A5 (cg-RX-API-DMAC7.html)
JP2021518400A5 (cg-RX-API-DMAC7.html)
JP2005523922A5 (cg-RX-API-DMAC7.html)
JP2012522759A5 (cg-RX-API-DMAC7.html)
JP2007527919A5 (cg-RX-API-DMAC7.html)
JP2011509302A5 (cg-RX-API-DMAC7.html)